Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apollomics Inc. - Warrant (NQ:APLMW)

0.0112 +0.0010 (+9.80%)
Delayed Quote Updated: 3:53 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apollomics Inc. - Warrant

< Previous 1 2 3 4 Next >
News headline image
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
From Apollomics Inc.
Via GlobeNewswire
News headline image
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
From Apollomics Inc.
Via GlobeNewswire
News headline image
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
From Apollomics Inc.
Via GlobeNewswire
News headline image
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
From Apollomics Inc.
Via GlobeNewswire
News headline image
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
From Apollomics Inc.
Via GlobeNewswire
News headline image
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
From Apollomics Inc.
Via GlobeNewswire
News headline image
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
From Apollomics Inc.
Via GlobeNewswire
News headline image
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Apollomics Inc.
Via GlobeNewswire
News headline image
Apollomics Co-Founder and President, Sanjeev Redkar, Ph.D., to Speak at 23rd Annual R. Bryan Miller Symposium
Dr. Redkar to discuss importance of HGF/cMET pathway, which can play critical role in origin of several cancers 
From Apollomics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.